Designed around Partners
with Scientific Depth

Our dedicated center model reflects the strength of our long-standing relationships with global pharmaceutical companies. It underpins our ability to support complex scientific programs with scientific rigor, operational excellence, transparency and flexibility. Designed as integrated extensions of customer research and development networks, these centers bring together dedicated infrastructure, multidisciplinary scientific talent and partner-aligned ways of working.

Enabling strategic partnership through deep scientific integration

Syngene’s collaboration with Bristol Myers Squibb is one of its longest-standing strategic relationships, beginning in 1998 and leading to the commissioning of its first dedicated R&D center in 2009. Over more than 25 years, this partnership has evolved into a deep and highly integrated engagement, with the Biocon Bristol Myers Squibb Research & Development Center (BBRC) becoming an important strategic R&D site within the customer’s global R&D network.

In January 2026, this collaboration was reaffirmed and extended through 2035, significantly broadening the scope of engagement across the drug development lifecycle. The expanded remit now spans discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization and reinforcing Syngene’s position as a strategic end-to-end partner.

Advancing development programs with quality and execution focus

Syngene also strengthened its collaboration with Baxter, supported by a renewed agreement through March 2028. The partnership expanded during the year with increased scientific capacity and continued recognition for meeting productivity and quality expectations. The Baxter Global Research Center (BGRC) supported a broad range of development and analytical activities, demonstrating Syngene’s ability to deliver high-quality outcomes.

Over the course of the year, the team successfully delivered full-cycle analytical services for multiple complex new product development projects. In addition, they supported a diverse portfolio of small and large molecule programs, facilitating timely global regulatory registrations and addressing critical patient needs in hospitals. The customer expressed appreciation for Syngene’s scientific expertise and problem-solving skills in areas such as new product development, nitrosamine testing, and nutrition compatibility. Furthermore, initiatives focused on enhancing capabilities, digitization, and continuous improvement effectively strengthened compliance, workflow efficiency, and delivery execution.